Core Viewpoint - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged again today, reaching a peak increase of 63% to HKD 679.5, marking a five-day cumulative rise of 863% and setting a new record since its IPO, with a market capitalization nearing HKD 270 billion [1] Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - The company currently has no commercialized products and reported zero revenue with a loss of HKD 123 million in the first half of this year [1] Clinical Development - On September 10, the company announced that its core product,替恩戈替尼 (TT-00420), in combination with fluorouracil, received implied approval from the National Medical Products Administration of China for a Phase II clinical trial targeting HR+/HER2- recurrent or metastatic breast cancer, expected to conclude by September 10, 2025 [1] - The trial is an open-label, multi-center study aimed at evaluating the safety, efficacy, and pharmacokinetics of the combination therapy [1]
营收为0！药捷安康上市不到3个月飙升50倍，市值逼近2700亿港元
Ge Long Hui·2025-09-16 02:34